4.3 Article

Sanfilippo syndrome type A: early cardiac involvement of two patients with cardiac manifestations

Journal

CARDIOVASCULAR PATHOLOGY
Volume 60, Issue -, Pages -

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.carpath.2022.107430

Keywords

Mucopolysaccharidosis type III; Sanfilippo syndrome; Heart; Transplantation; Autopsy

Ask authors/readers for more resources

This article reports two atypical presentations of mucopolysaccharidosis type III and provides evidence of cardiac involvement. Two siblings with Sanfilippo A syndrome were diagnosed in childhood, and one of them underwent a heart transplant at the age of 45 due to end-stage heart failure. The study of heart specimens revealed a thin right ventricular free wall, leading to a differential diagnosis with other cardiac diseases.
Purpose: To report two unusual presentations of mucopolysaccharidosis type III (Sanfilippo syndrome) and provide evidence for the cardiac involvement.Patients and methods: We report two siblings with cardiac involvement that were diagnosed in childhood with Sanfilippo A Syndrome (SAS). All patients' diagnosis was confirmed by the excess of heparan sulfate in the urine and the reduction of heparan sulfamidase protein activity. The heart specimens were studied. Results: We report two sibling patients (15-years-old female and 12-years-old female) occurring in sisters both with onset in childhood with no neurological, ophthalmic, hepatic symptoms or coarsening of features as classically described. Both patients underwent bilateral hip arthroplasty in their early 30's. The older sister had an orthotopic heart transplant because of end-stage heart failure of her cardiomyopathy at the age of 45. She is alive and well. The youngest sister died due to heart failure before a transplantation took place. In the two siblings a thin right ventricular free wall was seen, which triggered the differential diagnosis with arrhythmogenic right ventricular cardiomyopathy or lamin A/C cardiomyopathy. Conclusions: Early recognition of solitary or mainly cardiac involvement is essential for patients with mucopolysaccharidosis type III (SAS).(c) 2022 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available